Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Exon 20 Insertion Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04044170
What this trial is testing

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Hanmi Pharmaceutical Company Limited 5
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Large-scale testing (Phase 3)Active Not RecruitingNCT04538664
What this trial is testing

Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 308
Not applicableLooking for participantsNCT07563205
What this trial is testing

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer NSCLC+6 more
GFPC Investigation 100
Testing effectiveness (Phase 2)WithdrawnNCT04576208
What this trial is testing

Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Takeda
Testing effectiveness (Phase 2)Looking for participantsNCT05967689
What this trial is testing

Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Who this might be right for
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc. 220
Large-scale testing (Phase 3)Not Yet RecruitingNCT05767892
What this trial is testing

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Who this might be right for
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Suzhou Puhe Pharmaceutical Technology Co., LTD 350
Early research (Phase 1)WithdrawnNCT04958967
What this trial is testing

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT07182682
What this trial is testing

Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

Who this might be right for
Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd. 360
Early research (Phase 1)Not Yet RecruitingNCT05940116
What this trial is testing

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerSolid Tumor
Hansoh BioMedical R&D Company 322
Not applicableApproved For MarketingNCT04599712
What this trial is testing

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Active Not RecruitingNCT07274761
What this trial is testing

Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.

Who this might be right for
Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung CancerNon Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 24
Large-scale testing (Phase 3)Enrolling By InvitationNCT06281964
What this trial is testing

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 327
Early research (Phase 1)Study completedNCT04858958
What this trial is testing

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc. 90
Testing effectiveness (Phase 2)Looking for participantsNCT06706713
What this trial is testing

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
BeBetter Med Inc 200